Search

Your search keyword '"Leruste, Amaury"' showing total 41 results
Start Over Author "Leruste, Amaury"
41 results on '"Leruste, Amaury"'

1. Engineered CD47 protects T cells for enhanced antitumour immunity

Author

Yamada-Hunter, Sean A., Theruvath, Johanna, McIntosh, Brianna J., Freitas, Katherine A., Lin, Frank, Radosevich, Molly T., Leruste, Amaury, Dhingra, Shaurya, Martinez-Velez, Naiara, Xu, Peng, Huang, Jing, Delaidelli, Alberto, Desai, Moksha H., Good, Zinaida, Polak, Roel, May, Audre, Labanieh, Louai, Bjelajac, Jeremy, Murty, Tara, Ehlinger, Zach, Mount, Christopher W., Chen, Yiyun, Heitzeneder, Sabine, Marjon, Kristopher D., Banuelos, Allison, Khan, Omair, Wasserman, Savannah L., Spiegel, Jay Y., Fernandez-Pol, Sebastian, Kuo, Calvin J., Sorensen, Poul H., Monje, Michelle, Majzner, Robbie G., Weissman, Irving L., Sahaf, Bita, Sotillo, Elena, Cochran, Jennifer R., and Mackall, Crystal L.

Published
2024
Full Text
View/download PDF

2. Inosine induces stemness features in CAR-T cells and enhances potency

Author

Klysz, Dorota D., Fowler, Carley, Malipatlolla, Meena, Stuani, Lucille, Freitas, Katherine A., Chen, Yiyun, Meier, Stefanie, Daniel, Bence, Sandor, Katalin, Xu, Peng, Huang, Jing, Labanieh, Louai, Keerthi, Vimal, Leruste, Amaury, Bashti, Malek, Mata-Alcazar, Janette, Gkitsas, Nikolaos, Guerrero, Justin A., Fisher, Chris, Patel, Sunny, Asano, Kyle, Patel, Shabnum, Davis, Kara L., Satpathy, Ansuman T., Feldman, Steven A., Sotillo, Elena, and Mackall, Crystal L.

Published
2024
Full Text
View/download PDF

3. Childhood Langerhans cell histiocytosis hematological involvement: severity associated with BRAFV600E loads

Author

Thalhammer, Julian, Jeziorski, Eric, Marec-Bérard, Perrine, Barkaoui, Mohamed Aziz, Pagnier, Anne, Rohrlich, Pierre-Simon, Chevallier, Aurore, Carausu, Liana, Aladjidi, Nathalie, Rigaud, Charlotte, Leruste, Amaury, Azarnoush, Saba, Lauvray, Thomas, Le Louet, Solenne, Gandemer, Virginie, Treguier, Pauline, Mansuy, Ludovic, Pasquet, Marlene, Olivier, Laura, Rome, Angélique, Saultier, Paul, Isfan, Fiorentina, Renard, Cécile, Li Thiao Te, Valerie, Salmon, Alexandra, Blanc, Laurence, Abou Chahla, Wadih, Lambilliotte, Anne, Stephan, Jean-Louis, Geissmann, Frederic, Lejeune, Julien, Mallebranche, Coralie, Reguerre, Yves, Grain, Audrey, Thomas, Caroline, Hélias-Rodzewicz, Zofia, Moshous, Despina, Fenneteau, Odile, Coulomb-L’Hermine, Aurore, Lapillonne, Hélène, de Saint-Basile, Geneviève, Emile, Jean-François, Héritier, Sébastien, and Donadieu, Jean

Published
2024
Full Text
View/download PDF

4. Efficacy and safety of crizotinib in ALK-positive systemic anaplastic large-cell lymphoma in children, adolescents, and adult patients: results of the French AcSé-crizotinib trial

Author

Brugières, Laurence, Cozic, Nathalie, Houot, Roch, Rigaud, Charlotte, Sibon, David, Arfi-Rouche, Julia, Bories, Pierre, Cottereau, Anne S., Delmer, Alain, Ducassou, Stephane, Garnier, Nathalie, Lamant, Laurence, Leruste, Amaury, Millot, Frederic, Moalla, S., Morschhauser, Franck, Nolla, Marie, Pagnier, Anne, Reguerre, Yves, Renaud, Loic, Schmitt, Anne, Simonin, Mathieu, Verschuur, Arnaud, Hoog Labouret, Nathalie, Mahier Ait Oukhatar, Celine, and Vassal, Gilles

Published
2023
Full Text
View/download PDF

5. Outcome of childhood ALK‐positive anaplastic large cell lymphoma relapses: Real‐life experience of the French Society of Pediatric Oncology (SFCE) cohort of 75 French children.

Author

Pereira, Victor, Barthoulot, Maël, Aladjidi, Nathalie, Contet, Audrey, Dalle, Jean‐Hugues, Dourthe, Marie Émilie, Garnier, Nathalie, Bruno, Bénédicte, Leruste, Amaury, Pellier, Isabelle, Simonin, Matthieu, Paillard, Catherine, Verschuur, Arnauld, Ducassou, Stéphane, Lamant, Laurence, Brugieres, Laurence, Deley, Marie‐Cécile Le, and Rigaud, Charlotte

Published
2025
Full Text
View/download PDF

7. New Born and Infant Soft Tissue Sarcomas

Author

Butel, Thibault, Dumont, Benoit, Leruste, Amaury, Galmiche, Louise, Pierron, Gaëlle, Pannier, Stéphanie, Brisse, Hervé J., Minard-Colin, Véronique, Orbach, Daniel, Chevreau, Christine, editor, and Italiano, Antoine, editor

Published
2020
Full Text
View/download PDF

8. Long-Term Weight Gain in Children with Craniopharyngioma

Author

Rovani, Sibylle, primary, Butler, Victoria, additional, Samara-Boustani, Dinane, additional, Pinto, Graziella, additional, Gonzalez-Briceno, Laura, additional, Nguyen Quoc, Adrien, additional, Vermillac, Gaëlle, additional, Stoupa, Athanasia, additional, Besançon, Alix, additional, Beltrand, Jacques, additional, Thalassinos, Caroline, additional, Flechtner, Isabelle, additional, Dassa, Yamina, additional, Viaud, Magali, additional, Arrom-Branas, Maria Beatriz, additional, Boddaert, Nathalie, additional, Puget, Stéphanie, additional, Blauwblomme, Thomas, additional, Alapetite, Claire, additional, Bolle, Stéphanie, additional, Doz, François, additional, Grill, Jacques, additional, Dufour, Christelle, additional, Bourdeaut, Franck, additional, Abbou, Samuel, additional, Guerrini-Rousseau, Léa, additional, Leruste, Amaury, additional, Beccaria, Kévin, additional, Polak, Michel, additional, and Kariyawasam, Dulanjalee, additional

Published
2024
Full Text
View/download PDF

9. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors

Author

Theruvath, Johanna, Sotillo, Elena, Mount, Christopher W., Graef, Claus Moritz, Delaidelli, Alberto, Heitzeneder, Sabine, Labanieh, Louai, Dhingra, Shaurya, Leruste, Amaury, Majzner, Robbie G., Xu, Peng, Mueller, Sabine, Yecies, Derek W., Finetti, Martina A., Williamson, Daniel, Johann, Pascal D., Kool, Marcel, Pfister, Stefan, Hasselblatt, Martin, Fruhwald, Michael C., Delattre, Olivier, Surdez, Didier, Bourdeaut, Franck, Puget, Stephanie, Zaidi, Sakina, Mitra, Siddhartha S., Cheshier, Samuel, Sorensen, Poul H., Monje, Michelle, and Mackall, Crystal L.

Subjects
Care and treatment, Methods, Health aspects, Antigens -- Health aspects -- Methods, Cell therapy -- Methods -- Health aspects, Pediatric tumors -- Care and treatment, Nervous system tumors -- Care and treatment, T cells -- Health aspects -- Methods, Cellular therapy -- Methods -- Health aspects, Tumors in children -- Care and treatment
Abstract

Author(s): Johanna Theruvath [sup.1] , Elena Sotillo [sup.1] , Christopher W. Mount [sup.2] , Claus Moritz Graef [sup.1] , Alberto Delaidelli [sup.3] , Sabine Heitzeneder [sup.1] , Louai Labanieh [sup.1] [...], Atypical teratoid/rhabdoid tumors (ATRTs) typically arise in the central nervous system (CNS) of children under 3 years of age. Despite intensive multimodal therapy (surgery, chemotherapy and, if age permits, radiotherapy), median survival is 17 months.sup.1,2. We show that ATRTs robustly express B7-H3/CD276 that does not result from the inactivating mutations in SMARCB1 (refs. .sup.3,4), which drive oncogenesis in ATRT, but requires residual SWItch/Sucrose Non-Fermentable (SWI/SNF) activity mediated by BRG1/SMARCA4. Consistent with the embryonic origin of ATRT.sup.5,6, B7-H3 is highly expressed on the prenatal, but not postnatal, brain. B7-H3.BB.z-chimeric antigen receptor (CAR) T cells administered intracerebroventricularly or intratumorally mediate potent antitumor effects against cerebral ATRT xenografts in mice, with faster kinetics, greater potency and reduced systemic levels of inflammatory cytokines compared to CAR T cells administered intravenously. CAR T cells administered ICV also traffic from the CNS into the periphery; following clearance of ATRT xenografts, B7-H3.BB.z-CAR T cells administered intracerebroventricularly or intravenously mediate antigen-specific protection from tumor rechallenge, both in the brain and periphery. These results identify B7-H3 as a compelling therapeutic target for this largely incurable pediatric tumor and demonstrate important advantages of locoregional compared to systemic delivery of CAR T cells for the treatment of CNS malignancies. CAR T cells administered intracerebroventricularly or intratumorally exhibit more rapid kinetics, reduced systemic toxicity and greater therapeutic potency as compared to intravenously delivered CAR T cells in atypical teratoid/rhabdoid tumor xenograft mouse models.

Published
2020
Full Text
View/download PDF

10. 275 Inosine endows CAR T cells with features of increased stemness and anti-tumor potency

Author

Klysz, Dorota, primary, Fowler, Carley, additional, Malipatlolla, Meena, additional, Stuani, Lucille, additional, Freitas, Katherine A, additional, Meier, Stefanie, additional, Daniel, Bence, additional, Sandor, Katalin, additional, Xu, Peng, additional, Huang, Jing, additional, Labanieh, Louai, additional, Leruste, Amaury, additional, Bashti, Malek, additional, Mata-Alcazar, Janette, additional, Keerthi, Vimal, additional, Gkitsas, Nikolaos, additional, Guerrero, Justin A, additional, Fisher, Chris, additional, Patel, Sunny, additional, Asano, Kyle, additional, Patel, Shabnum, additional, Davis, Kara L, additional, Satpathy, Ansuman T, additional, Feldman, Steven A, additional, Sotillo, Elena, additional, and Mackall, Crystal L, additional

Published
2023
Full Text
View/download PDF

11. Measuring Safety and Outcomes for the Use of Compassionate and Off-Label Therapies for Children, Adolescents, and Young Adults With Cancer in the SACHA-France Study

Author

Berlanga, Pablo, primary, Ndounga-Diakou, Lee Aymar, additional, Aerts, Isabelle, additional, Corradini, Nadège, additional, Ducassou, Stéphane, additional, Strullu, Marion, additional, de Carli, Emilie, additional, André, Nicolas, additional, Entz-Werle, Natacha, additional, Raimbault, Sandra, additional, Roumy, Marianne, additional, Renouard, Marjolaine, additional, Gueguen, Gwenaelle, additional, Plantaz, Dominique, additional, Reguerre, Yves, additional, Cleirec, Morgane, additional, Petit, Arnaud, additional, Puiseux, Chloe, additional, Andry, Leslie, additional, Klein, Sébastien, additional, Bodet, Damien, additional, Kanold, Justyna, additional, Briandet, Claire, additional, Halfon-Domenech, Carine, additional, Nelken, Brigitte, additional, Piguet, Christophe, additional, Saumet, Laure, additional, Chastagner, Pascal, additional, Benadiba, Joy, additional, Millot, Frédéric, additional, Pluchart, Claire, additional, Schneider, Pascale, additional, Thouvenin, Sandrine, additional, Gambart, Marion, additional, Serre, Jill, additional, Abbou, Samuel, additional, Leruste, Amaury, additional, Cayzac, Hélena, additional, Gandemer, Virginie, additional, Laghouati, Salim, additional, and Vassal, Gilles, additional

Published
2023
Full Text
View/download PDF

12. Inosine Induces Stemness Features in CAR T cells and Enhances Potency

Author

Klysz, Dorota D., primary, Fowler, Carley, additional, Malipatlolla, Meena, additional, Stuani, Lucille, additional, Freitas, Katherine A., additional, Meier, Stefanie, additional, Daniel, Bence, additional, Sandor, Katalin, additional, Xu, Peng, additional, Huang, Jing, additional, Labanieh, Louai, additional, Leruste, Amaury, additional, Bashti, Malek, additional, Keerthi, Vimal, additional, Mata-Alcazar, Janette, additional, Gkitsas, Nikolaos, additional, A. Guerrero, Justin, additional, Fisher, Chris, additional, Patel, Sunny, additional, Asano, Kyle, additional, Patel, Shabnum, additional, L. Davis, Kara, additional, Satpathy, Ansuman T., additional, Feldman, Steven A., additional, Sotillo, Elena, additional, and Mackall, Crystal L., additional

Published
2023
Full Text
View/download PDF

13. Abstract 5741: Harnessing macrophages, while protecting T cells, enhances anti-tumor efficacy

Author

Yamada-Hunter, Sean A., primary, Theruvath, Johanna, additional, Radosevich, Molly T., additional, McIntosh, Brianna J., additional, Freitas, Katherine A., additional, Martinez-Velez, Naiara, additional, Sotillo, Elena, additional, Leruste, Amaury, additional, Xu, Peng, additional, Desai, Moksha H., additional, Sahaf, Bita, additional, Banuelos, Allison, additional, Wasserman, Savannah L., additional, Weissman, Irving L., additional, Cochran, Jennifer R., additional, and Mackall, Crystal L., additional

Published
2023
Full Text
View/download PDF

14. Abstract 1158: Inosine endows CAR T cells with features of increased stemness and anti-tumor potency

Author

Klysz, Dorota, primary, Freitas, Katie, additional, Malipatlolla, Meena, additional, Maier, Stefanie, additional, Fowler, Carley, additional, Labanieh, Louai, additional, Stuani, Lucille, additional, Daniel, Bence, additional, Sandor, Katalin, additional, Xu, Peng, additional, Huang, Jing, additional, Leruste, Amaury, additional, Keerthi, Vimal, additional, Gkitsas, Nikolaos, additional, Patel, Shabnum, additional, Arredondo-Guerrero, Justin, additional, Fisher, Chris, additional, Asano, Kyle, additional, Patel, Sunny, additional, Satpathy, Ansuman, additional, Davis, Kara, additional, Sotillo, Elena, additional, Feldman, Steven, additional, and Mackall, Crystal, additional

Published
2023
Full Text
View/download PDF

16. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

Author

Nguyen Quoc, Adrien, primary, Beccaria, Kévin, additional, González Briceño, Laura, additional, Pinto, Graziella, additional, Samara-Boustani, Dinane, additional, Stoupa, Athanasia, additional, Beltrand, Jacques, additional, Besançon, Alix, additional, Thalassinos, Caroline, additional, Puget, Stéphanie, additional, Blauwblomme, Thomas, additional, Alapetite, Claire, additional, Bolle, Stéphanie, additional, Doz, François, additional, Grill, Jacques, additional, Dufour, Christelle, additional, Bourdeaut, Franck, additional, Abbou, Samuel, additional, Guerrini-Rousseau, Léa, additional, Leruste, Amaury, additional, Brabant, Séverine, additional, Cavadias, Iphigénie, additional, Viaud, Magali, additional, Boddaert, Nathalie, additional, Polak, Michel, additional, and Kariyawasam, Dulanjalee, additional

Published
2023
Full Text
View/download PDF

17. GH and Childhood-onset Craniopharyngioma: When to Initiate GH Replacement Therapy?

Author

Quoc, Adrien Nguyen, Beccaria, Kévin, Briceño, Laura González, Pinto, Graziella, Samara-Boustani, Dinane, Stoupa, Athanasia, Beltrand, Jacques, Besançon, Alix, Thalassinos, Caroline, Puget, Stéphanie, Blauwblomme, Thomas, Alapetite, Claire, Bolle, Stéphanie, Doz, François, Grill, Jacques, Dufour, Christelle, Bourdeaut, Franck, Abbou, Samuel, Guerrini-Rousseau, Léa, and Leruste, Amaury

Subjects
CRANIOPHARYNGIOMA, BENIGN tumors
Abstract

Context: Craniopharyngioma is a benign brain tumor with frequent local recurrence or progression after treatment. GH replacement therapy (GHRT) is prescribed in children with GH deficiency resulting from childhood-onset craniopharyngioma. Objective: To evaluate whether a shorter delay of GHRT initiation after childhood-onset craniopharyngioma completion therapy increased the risk of a new event (progression or recurrence). Methods: Retrospective, observational, monocenter study. We compared a cohort of 71 childhood-onset patients with craniopharyngiomas treated with recombinant human GH (rhGH). Twenty-seven patients were treated with rhGH at least 12 months after craniopharyngioma treatment (>12-month group) and 44 patients before 12 months (<12-month group), among which 29 patients were treated between 6 and 12 months (6-12 month group). The main outcome was the risk of tumor new event (progression of residual tumor or tumor recurrence after complete resection) after primary treatment in the >12-month group and in the <12 month or in the 6- to 12-month group patients. Results: In the >12-month group, the 2- and 5-year event-free survivals were respectively 81.5% (95% CI, 61.1-91.9) and 69.4% (95% CI, 47.9- 83.4) compared with 72.2% (95% CI, 56.3-83.1) and 69.8% (95% CI, 53.8-81.2) in the <12-month group. The 2- and 5-year event-free survivals were the same in the 6- to 12-month group (72.4%; 95% CI, 52.4-85.1). By log-rank test, the event-free survival was not different between groups (P = .98 and P = .91). The median time for event was not statistically different. In univariate and multivariate analysis, the risk of craniopharyngioma new event was not associated with the GHRT time delay after craniopharyngioma treatment. Conclusions: No association was found between GHRT time delay after childhood-onset craniopharyngioma treatment and an increased risk of recurrence or tumor progression, suggesting GH replacement therapy can be initiated 6 months after last treatment for craniopharyngiomas. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

20. Rituximab in addition to LMB-based chemotherapy regimen in children and adolescents with primary mediastinal large B-cell lymphoma: results of the French LMB2001 prospective study

Author

Dourthe, Marie Emilie, primary, Phulpin, Aurélie, additional, Auperin, Anne, additional, Bosq, Jacques, additional, Couec, Marie-Laure, additional, Dartigues, Peggy, additional, Ducassou, Stéphane, additional, Garnier, Nathalie, additional, Haouy, Stéphanie, additional, Leblanc, Thierry, additional, Leruste, Amaury, additional, Paillard, Catherine, additional, Rigaud, Charlotte, additional, Simonin, Mathieu, additional, Patte, Catherine, additional, and Minard-Colin, Véronique, additional

Published
2022
Full Text
View/download PDF

21. Epstein-Barr Virus in Childhood and Adolescent Classic Hodgkin Lymphoma in a French Cohort of 301 Patients

Author

Pereira, Victor, primary, Boudjemaa, Sabah, additional, Besson, Caroline, additional, Leblanc, Thierry, additional, Rigaud, Charlotte, additional, Leruste, Amaury, additional, Garnier, Nathalie, additional, Lambilliotte, Anne, additional, Simonin, Matthieu, additional, Curtillet, Catherine, additional, Bonneau-Lagacherie, Jacinthe, additional, Coulomb, Aurore, additional, and Landman-Parker, Judith, additional

Published
2022
Full Text
View/download PDF

22. SMARCA4 ‐deficient rhabdoid tumours show intermediate molecular features between SMARCB1 ‐deficient rhabdoid tumours and small cell carcinomas of the ovary, hypercalcaemic type

Author

Andrianteranagna, Mamy, primary, Cyrta, Joanna, additional, Masliah‐Planchon, Julien, additional, Nemes, Karolina, additional, Corsia, Alice, additional, Leruste, Amaury, additional, Holdhof, Dörthe, additional, Kordes, Uwe, additional, Orbach, Daniel, additional, Corradini, Nadège, additional, Entz‐Werle, Natacha, additional, Pierron, Gaëlle, additional, Castex, Marie‐Pierre, additional, Brouchet, Anne, additional, Weingertner, Noëlle, additional, Ranchère, Dominique, additional, Fréneaux, Paul, additional, Delattre, Olivier, additional, Bush, Jonathan, additional, Leary, Alexandra, additional, Frühwald, Michael C, additional, Schüller, Ulrich, additional, Servant, Nicolas, additional, and Bourdeaut, Franck, additional

Published
2021
Full Text
View/download PDF

23. Hematological Involvement in Childhood Langerhans Cell Histiocytosis: A Cohort Study of 303 Patients

Author

Thalhammer, Julian, Marec-Bérard, Perrine, Barkaoui, Mohamed, Jeziorski, Eric, Rome, Angelique, Pagnier, Anne, Rohrlich, Pierre Simon, Aladjidi, Nathalie, Rigaud, Charlotte, Leruste, Amaury, Azarnoush, Saba, Lauvray, Thomas, Le Louet, Solenne, Gandemer, Virginie, Treguier, Pauline, Mansuy, Ludovic, Pasquet, Marlène, Olivier, Laura, Isfan, Florentina, Renard, Cécile, Salmon, Alexandra, Blanc, Laurence, Abou Chahla, Wadih, Lambilliotte, Anne, Mallebranche, Coralie, Thomas, Caroline, Moshous, Despina, de Saint-Basile, Genevieve, Emile, Jean-Francois, Héritier, Sébastien, and Donadieu, Jean

Published
2023
Full Text
View/download PDF

24. Epstein Barr Virus in childhood and adolescent classical Hodgkin lymphoma in a French cohort of 301 patients

Author

Pereira, Victor, primary, Boudjemaa, Sabah, additional, Besson, Caroline, additional, Leblanc, Thierry, additional, Rigaud, Charlotte, additional, Leruste, Amaury, additional, Garnier, Nathalie, additional, Lambilliotte, Anne, additional, Simonin, Mathieu, additional, Curtillet, Catherine, additional, Bonneau-Lagacherie, Jacinthe, additional, L'HERMINE, Aurore COULOMB, additional, and Landman-Parker, Judith, additional

Published
2021
Full Text
View/download PDF

27. Abstract B68: Spatial and temporal conditions for Smarcb1 deletion determines mouse AT/RT (atypical teratoid/rhabdoid tumor) subtype

Author

Han, Zhi-Yan, primary, Andrianteranagna, Mamy, additional, Jesus-Lobon-Iglesias, Maria, additional, Tauziède-Espariat, Arnault, additional, Beccaria, Kevin, additional, Fréneaux, Paul, additional, Waterfall, Joshua J., additional, Masliah-Planchon, Julien, additional, Bourneix, Christine, additional, Pierron, Gaelle, additional, Leruste, Amaury, additional, Chauvin, Céline, additional, Surdez, Didier, additional, Varlet, Pascale, additional, Dufour, Christelle, additional, Delattre, Olivier, additional, Dangouloff-Ros, Volodia, additional, and Bourdeaut, Franck, additional

Published
2020
Full Text
View/download PDF

28. Clonally Expanded T Cells Reveal Immunogenicity of Rhabdoid Tumors

Author

Leruste, Amaury, primary, Tosello, Jimena, additional, Ramos, Rodrigo Nalio, additional, Tauziède-Espariat, Arnault, additional, Brohard, Solène, additional, Han, Zhi-Yan, additional, Beccaria, Kevin, additional, Andrianteranagna, Mamy, additional, Caudana, Pamela, additional, Nikolic, Jovan, additional, Chauvin, Céline, additional, Niborski, Leticia Laura, additional, Manriquez, Valeria, additional, Richer, Wilfrid, additional, Masliah-Planchon, Julien, additional, Grossetête-Lalami, Sandrine, additional, Bohec, Mylene, additional, Lameiras, Sonia, additional, Baulande, Sylvain, additional, Pouponnot, Celio, additional, Coulomb, Aurore, additional, Galmiche, Louise, additional, Surdez, Didier, additional, Servant, Nicolas, additional, Helft, Julie, additional, Sedlik, Christine, additional, Puget, Stéphanie, additional, Benaroch, Philippe, additional, Delattre, Olivier, additional, Waterfall, Joshua J., additional, Piaggio, Eliane, additional, and Bourdeaut, Franck, additional

Published
2019
Full Text
View/download PDF

29. High-Throughput Drug Screening Identifies Pazopanib and Clofilium Tosylate as Promising Treatments for Malignant Rhabdoid Tumors

Author

Chauvin, Céline, Leruste, Amaury, Tauziede-Espariat, Arnault, Andrianteranagna, Mamy, Surdez, Didier, Lescure, Aurianne, Han, Zhi-Yan, Anthony, Elodie, Richer, Wilfrid, Baulande, Sylvain, Bohec, Mylène, Zaidi, Sakina, Aynaud, Marie-Ming, Maillot, Laetitia, Masliah-Planchon, Julien, Cairo, Stefano, Roman-Roman, Sergio, Delattre, Olivier, Del Nery, Elaine, and Bourdeaut, Franck

Published
2017
Full Text
View/download PDF

30. Immune responses in genomically simple SWI/SNF–deficient cancers.

Author

Leruste, Amaury, Chauvin, Céline, Pouponnot, Celio, Bourdeaut, Franck, Waterfall, Joshua J., and Piaggio, Eliane

Subjects
*IMMUNE response, *RADIOTHERAPY, *SUCROSE
Abstract

Switch/sucrose nonfermentable–deficient cancers may respond to immune checkpoint blockade. Combinations with epidrugs or radiation therapies can offer new specific therapeutic vulnerabilities. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

31. Abstract PR03: Analysis of immune infiltrate identifies checkpoint blockade and TLR3 activation as efficient synergistic combination of immunotherapy in rhabdoid tumors

Author

Leruste, Amaury, primary, Han, Zhi-Yan, additional, Tauziède-Espariat, Arnault, additional, Caudana, Pamela, additional, Waterfall, Joshua J., additional, Andrianteranagna, Mamy, additional, Sedlik, Christine, additional, Ramos, Rodrigo, additional, Viel, Sophie, additional, Chauvin, Céline, additional, Delattre, Olivier, additional, Piaggio, Eliane, additional, and Bourdeaut, Franck, additional

Published
2018
Full Text
View/download PDF

32. ATRT-35. SMARCB1-DEFICIENT TUMORS ACTIVATE BOTH INNATE AND ADAPTIVE IMMUNE RESPONSES AND ARE SUSCEPTIBLE TO CHECKPOINT BLOCKADE AND TLR3 ACTIVATION

Author

Leruste, Amaury, primary, Caudana, Pamela, additional, Tauziede-Espariat, Arnault, additional, Han, Zhi-Yan, additional, Ramos, Rodrigo N, additional, Nikolic, Jovan, additional, Tosello, Jimena, additional, Brohard, Solene, additional, Andrianteranagna, Mamy, additional, Chauvin, Céline, additional, Masliah-Planchon, Julien, additional, Sedlick, Christine, additional, Coulomb, Aurore, additional, Galmiche-Rolland, Louise, additional, Ranchere, Dominique, additional, Benaroch, Philippe, additional, Waterfall, Joshua J, additional, Delattre, Olivier, additional, Piaggio, Eliane, additional, and Bourdeaut, Franck, additional

Published
2018
Full Text
View/download PDF

33. ATRT-10. SPATIO-TEMPORAL DELETION OF SMARCB1 DETERMINES MOUSE AT/RT SUBTYPES

Author

Han, Zhi-Yan, primary, Andrianteranagna, Mamy, additional, Tauziède-Espariat, Arnault, additional, Fréneaux, Paul, additional, Masliah-Planchon, Julien, additional, Bourneix, Christine, additional, Pierron, Gaelle, additional, Leruste, Amaury, additional, Chauvin, Céline, additional, Varlet, Pascale, additional, Surdez, Didier, additional, Delattre, Olivier, additional, and Bourdeaut, Franck, additional

Published
2018
Full Text
View/download PDF

34. HighhThroughput Drug Screening Identifies Pazopanib and Clofilium Tosylate As Promising Treatments for Malignant Rhabdoid Tumors

Author

Chauvin, CCline, primary, Leruste, Amaury, additional, Tauziede-Espariat, Arnault, additional, Surdez, Didier, additional, Richer, Wilfrid, additional, Lescure, Aurianne, additional, Han, Zhi-Yan, additional, Anthony, Elodie, additional, Zaidi, Sakina, additional, Aynaud, Marie-Ming, additional, Maillot, Laetitia, additional, Masliah-Planchon, Julien, additional, Cairo, Stefano, additional, Roman-Roman, Sergio, additional, Delattre, Olivier, additional, Del Nery, Elaine, additional, and Bourdeaut, Franck, additional

Published
2018
Full Text
View/download PDF

35. Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers

Author

Richer, Wilfrid, primary, Masliah-Planchon, Julien, additional, Clement, Nathalie, additional, Jimenez, Irene, additional, Maillot, Laetitia, additional, Gentien, David, additional, Albaud, Benoît, additional, Chemlali, Walid, additional, Galant, Christine, additional, Larousserie, Frederique, additional, Boudou-Rouquette, Pascaline, additional, Leruste, Amaury, additional, Chauvin, Celine, additional, Han, Zhi Yan, additional, Coindre, Jean-Michel, additional, Varlet, Pascale, additional, Freneaux, Paul, additional, Ranchère-Vince, Dominique, additional, Delattre, Olivier, additional, and Bourdeaut, Franck, additional

Published
2017
Full Text
View/download PDF

36. Embryonic signature distinguishes pediatric and adult rhabdoid tumors from other SMARCB1-deficient cancers.

Author

UCL - (SLuc) Service d'anatomie pathologique, Richer, Wilfrid, Masliah-Planchon, Julien, Clement, Nathalie, Jimenez, Irene, Maillot, Laetitia, Gentien, David, Albaud, Benoît, Chemlali, Walid, Galant, Christine, Larousserie, Frederique, Boudou-Rouquette, Pascaline, Leruste, Amaury, Chauvin, Celine, Han, Zhi Yan, Coindre, Jean-Michel, Varlet, Pascale, Freneaux, Paul, Ranchère-Vince, Dominique, Delattre, Olivier, Bourdeaut, Franck, UCL - (SLuc) Service d'anatomie pathologique, Richer, Wilfrid, Masliah-Planchon, Julien, Clement, Nathalie, Jimenez, Irene, Maillot, Laetitia, Gentien, David, Albaud, Benoît, Chemlali, Walid, Galant, Christine, Larousserie, Frederique, Boudou-Rouquette, Pascaline, Leruste, Amaury, Chauvin, Celine, Han, Zhi Yan, Coindre, Jean-Michel, Varlet, Pascale, Freneaux, Paul, Ranchère-Vince, Dominique, Delattre, Olivier, and Bourdeaut, Franck

Abstract

Extra-cranial rhabdoid tumors (RT) are highly aggressive malignancies of infancy, characterized by undifferentiated histological features and loss of SMARCB1 expression. The diagnosis is all the more challenging that other poorly differentiated cancers lose SMARCB1 expression, such as epithelioid sarcomas (ES), renal medullary carcinomas (RMC) or undifferentiated chordomas (UC). Moreover, late cases occurring in adults are now increasingly reported, raising the question of differential diagnoses and emphasizing nosological issues. To address this issue, we have analyzed the expression profiles of a training set of 32 SMARCB1-deficient tumors (SDT), with ascertained diagnosis of RT (n = 16, all < 5 years of age), ES (n = 8, all > 10 years of age), UC (n = 3) and RMC (n = 5). As compared with other SDT, RT are characterized by an embryonic signature, and up-regulation of key-actors of de novo DNA methylation processes. Using this signature, we then analysed the expression profiling of 37 SDT to infer the appropriate diagnosis. Thirteen adult onset tumors showed strong similarity with pediatric RT, in spite of older age; by exome sequencing, these tumors also showed genomic features indistinguishable from pediatric RT. In contrary, 8 tumors were reclassified within carcinoma, ES or UC categories, while the remaining could not be related to any of those entities. Our results demonstrate that embryonic signature is shared by all RT, whatever the age at diagnosis; they also illustrate that many adult-onset SDT of ambiguous histological diagnosis are clearly different from RT. Finally, our study paves the way for the routine use of expression-based signatures to give accurate diagnosis of SDT.

Published
2017

39. Excellent outcome of children/adolescents with primary mediastinal large B-cell lymphoma treated with a FAB/ LMB-based chemotherapy regimen with rituximab.

Author

Dourthe ME, Auperin A, Rigaud C, Barbati M, Bonneau J, Buchbinder N, Couec ML, Dartigues P, Ducassou S, Garnier N, Haouy S, Jonca B, Jourdain A, Leruste A, Molina T, Montravers F, Pasquet M, Phulpin A, Poirée M, Simonin M, Spiegel A, Verschuur A, Leblanc T, Landman-Parker J, Patte C, and Minard-Colin V

Published
2024
Full Text
View/download PDF

40. Molecular and clinicopathologic characterization of pediatric histiocytoses.

Author

Hélias-Rodzewicz Z, Donadieu J, Terrones N, Barkaoui MA, Lambilliotte A, Moshous D, Thomas C, Azarnoush S, Pasquet M, Mansuy L, Aladjidi N, Jeziorski E, Marec-Berard P, Gilibert-Yvert M, Spiegel A, Saultier P, Pellier I, Pagnier A, Pertuisel S, Poiree M, Bodet D, Millot F, Isfan F, Stephan JL, Leruste A, Rigaud C, Filhon B, Carausu L, Reguerre Y, Kieffer I, Brichard B, Ben Jannet R, Bakari M, Idbaih A, Bodemer C, Cohen-Aubart F, Haroche J, Tazi A, Boudjemaa S, Fraitag S, Emile JF, and Heritier S

Subjects
Humans, Child, Proto-Oncogene Proteins B-raf genetics, Mutation, Exons, Histiocytosis, Langerhans-Cell genetics, Erdheim-Chester Disease genetics
Abstract

The spectrum of somatic mutations in pediatric histiocytoses and their clinical implications are not fully characterized, especially for non-Langerhans cell histiocytosis (-LCH) subtypes. A cohort of 415 children with histiocytosis from the French histiocytosis registry was reviewed and analyzed for BRAF V600E . Most BRAF WT samples were analyzed by next-generation sequencing (NGS) with a custom panel of genes for histiocytosis and myeloid neoplasia. Of 415 case samples, there were 366 LCH, 1 Erdheim-Chester disease, 21 Rosai-Dorfman disease (RDD), 21 juvenile xanthogranuloma (JXG, mostly with severe presentation), and 6 malignant histiocytosis (MH). BRAF V600E was the most common mutation found in LCH (50.3%, n = 184). Among 105 non-BRAF V600E -mutated LCH case samples, NGS revealed mutations as follows: MAP2K1 (n = 44), BRAF exon 12 deletions (n = 26), and duplications (n = 8), other BRAF V600 codon mutation (n = 4), and non-MAP-kinase pathway genes (n = 5). Wild-type sequences were identified in 17.1% of samples. BRAF V600E was the only variant significantly correlated with critical presentations: organ-risk involvement and neurodegeneration. MAP-kinase pathway mutations were identified in seven RDD (mostly MAP2K1) and three JXG samples, but most samples were wild-type on NGS. Finally, two MH samples had KRAS mutations, and one had a novel BRAF G469R mutation. Rarely, we identified mutations unrelated to MAP-kinase pathway genes. In conclusion, we characterized the mutational spectrum of childhood LCH and clinical correlations of variants and subtypes. Variants responsible for JXG and RDD were not elucidated in more than half of the cases, calling for other sequencing approaches., (© 2023 The Authors. American Journal of Hematology published by Wiley Periodicals LLC.)

Published
2023
Full Text
View/download PDF

41. Inosine Induces Stemness Features in CAR T cells and Enhances Potency.

Author

Klysz DD, Fowler C, Malipatlolla M, Stuani L, Freitas KA, Meier S, Daniel B, Sandor K, Xu P, Huang J, Labanieh L, Leruste A, Bashti M, Keerthi V, Mata-Alcazar J, Gkitsas N, Guerrero JA, Fisher C, Patel S, Asano K, Patel S, Davis KL, Satpathy AT, Feldman SA, Sotillo E, and Mackall CL

Abstract

Adenosine (Ado) mediates immune suppression in the tumor microenvironment and exhausted CD8 + CAR T cells mediate Ado-induced immunosuppression through CD39/73-dependent Ado production. Knockout of CD39, CD73 or A2aR had modest effects on exhausted CAR T cells, whereas overexpression of Ado deaminase (ADA), which metabolizes Ado to inosine (INO), induced stemness features and potently enhanced functionality. Similarly, and to a greater extent, exposure of CAR T cells to INO augmented CAR T cell function and induced hallmark features of T cell stemness. INO induced a profound metabolic reprogramming, diminishing glycolysis and increasing oxidative phosphorylation, glutaminolysis and polyamine synthesis, and modulated the epigenome toward greater stemness. Clinical scale manufacturing using INO generated enhanced potency CAR T cell products meeting criteria for clinical dosing. These data identify INO as a potent modulator of T cell metabolism and epigenetic stemness programming and deliver a new enhanced potency platform for immune cell manufacturing., Competing Interests: Conflict of interests D.D.K, S.A.F., and C.L.M. are co-inventors on a pending patent application number 63/358,996 for inosine media supplementation during cell manufacturing. D.D.K and C.L.M. are inventors on a patent application number PCT/US2022/075584 that covers the use of T cells overexpressing ADA1/2 for cancer immunotherapy. C.L.M. is a cofounder of and holds equity in Lyell Immunopharma and Link Cell Therapies. C.L.M., and L.L. are co-founders of and hold equity in CARGO Therapeutics. L.L. consults for and holds equity in Lyell Immunopharma. E.S holds equity in Lyell Immunopharma and consults for Lepton Pharmaceuticals and Galaria. S.A.F. serves on the Scientific Advisory Boards for Alaunos Therapeutics and Fresh Wind Biotech and has equity interest in both; S.A.F. receives research funding from CARGO and Tune Therapeutics. S.P. is a current employee of and holds equity in CARGO. C.L.M. consults for Lyell, CARGO, Link, Apricity, Nektar, Immatics, Mammoth, and Ensoma. A.T.S. is a cofounder of Immunai and Cartography Biosciences. A.T.S. receives research funding from Allogene Therapeutics and Merck Research Laboratories.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results